Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Receivables (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Receivables for 16 consecutive years, with $115.3 million as the latest value for Q4 2025.

  • Quarterly Receivables fell 4.87% to $115.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $115.3 million through Dec 2025, down 4.87% year-over-year, with the annual reading at $115.3 million for FY2025, 4.87% down from the prior year.
  • Receivables for Q4 2025 was $115.3 million at Myriad Genetics, down from $118.0 million in the prior quarter.
  • The five-year high for Receivables was $137.0 million in Q2 2025, with the low at $91.3 million in Q4 2021.
  • Average Receivables over 5 years is $111.3 million, with a median of $114.8 million recorded in 2023.
  • Peak annual rise in Receivables hit 33.52% in 2021, while the deepest fall reached 8.1% in 2021.
  • Over 5 years, Receivables stood at $91.3 million in 2021, then grew by 11.28% to $101.6 million in 2022, then rose by 12.5% to $114.3 million in 2023, then rose by 6.04% to $121.2 million in 2024, then dropped by 4.87% to $115.3 million in 2025.
  • According to Business Quant data, Receivables over the past three periods came in at $115.3 million, $118.0 million, and $137.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.